Immunis Teams Up with Toray to Combat Sarcopenia

IRVINE, Calif.-- Immunis, Inc., a clinical-stage biotech enterprise focusing on innovative secretome therapies to combat age-related diseases and immune dysfunction, has achieved a significant milestone by partnering with Toray, a Japanese pharmaceutical company within the Toray Group. Established in 1926, Toray has evolved into a successful conglomerate renowned for addressing critical global health and environmental issues. Toray's diverse expertise spans across various industries including pharmaceuticals, electronics, textiles, and aerospace, supported by advanced materials science production.

Immunis has secured the development and commercial rights for TRK-820, a Japan-approved drug and an opioid receptor agonist originally developed for treating severe itching, also known as pruritus. Pre-clinical studies indicate that Immunis' formulation of TRK-820 holds promise for treating sarcopenia, a condition characterized by age-related muscle loss. This drug may complement IMMUNA, Immunis’ human-derived regenerative biologic that has shown potential to reverse muscle deterioration, promote muscle growth, and enhance metabolism.

Currently, Immunis is conducting independent validations to evaluate TRK-820's effectiveness in reversing sarcopenia. The company plans to apply for a Phase 2 clinical trial to further assess the drug's efficacy in humans. One significant advantage of TRK-820 is its oral administration, providing a different mechanism of action from IMMUNA and potentially enhancing muscle regeneration in humans.

Both Immunis and Toray share the mission of advancing healthcare and improving the quality of life. Immunis is optimistic about the prospects this partnership offers in tackling sarcopenia collaboratively.

Immunis Inc. is a private biotechnology firm committed to developing innovative immunomodulatory secretome products aimed at various age and disease-related immune declines. The company's investigational product line uses Immunis' leading-edge secretome technology to deliver natural, human immune modulators in their natural physiological concentrations.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!